Updated Jul. 24, 2013 at 10:33 a.m.

Premium Lock Orphan disease drug from BioCryst a winner? Too early to tell

Published: 2013-07-23 19:01:00
Updated: 2013-07-24 10:33:25

Print this blog post
BioCryst's BCX4161 BioCryst's BCX4161

BioCryst experimental drug for hereditary angiodema has traits setting it apart from other HAE drugs but it's got a long way to go before it reaches patients. Read more about the company's plans....

Read More
Read More

WRAL Tech Wire any time: Twitter, Facebook

Copyright 2014 WRAL Tech Wire. All rights reserved.
Editor's Blog

Editor's Blog

The latest blog posts from our WRAL Tech Wire and WRAL editors. Read more articles…

Please Log In to add a comment.

Best of TechWire Insider

Techwire Inside Partners

OUR INSIDERS

Frank Vinluan
Life science
Vivek Wadhwa
Commentary
Dr. Mike Walden
Tech economy
Scroll